🔎 Trials Near Me

መነሻ › Metastatic Cancer › New Mexico

በNew Mexico ለMetastatic Cancer የሚደረጉ ክሊኒካዊ ጥናቶች

ለMetastatic Cancer የሚደረጉ 13 ጥናቶች በNew Mexico ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በNew Mexico ውስጥ ያሉ ከተሞች

Official study text (English)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • University of New Mexico Cancer Center, Albuquerque
ተሳታዮችን በመፈለግ ላይደረጃ 2
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05564377

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  • University of New Mexico Comprehensive Cancer Center, Albuquerque
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT06943755

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  • University of New Mexico Comprehensive Cancer Center, Albuquerque
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07222800

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • University of New Mexico Comprehensive Cancer Center, Albuquerque
  • CHRISTUS St. Vincent Regional Cancer Center, Santa Fe
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07222566

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  • Research Site, Albuquerque
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06103864

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

  • New Mexico Oncology Hematology Consultants, Albuquerque
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07028489

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Optimum Clinical Research Group, Albuquerque
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07213804

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of New Mexico Comprehensive Cancer Center, Albuquerque
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT06119581

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  • Research Site, Albuquerque
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሴቶች · የተሻሻለው በ29 ጁላይ 2026 · NCT07044336

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • Christus St Vincent Regional Medical Center, Santa Fe
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ጁላይ 2026 · NCT06657144

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

  • New Mexico Oncology Hematology Consultants Ltd, Albuquerque
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ወንዶች · የተሻሻለው በ4 ፌብሩ 2026 · NCT04729114

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  • Presbyterian Kaseman Hospital (site 208), Albuquerque
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ11 ዲሴም 2025 · NCT03556228

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Albuquerque
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦክቶ 2025 · NCT03452774

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።